Study Phase | Screening | Treatment visit | Treatment visit | Treatment visit | Treatment visit | Treatment visit | Postop visit | Postop visit | Follow up visit | Follow up visit | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Therapy | Nivolumab cycle 1 | Nivolumab cycle 2 | Nivolumab cycle 3 | Nivolumab cycle 4 | End RIT/PreOP | Postop 6w | Postop 12w | Follow up 6 m postop | Follow up 12 m postop | |||
Timepoint | -d28 – d0 | d1 (w1d1) | d15 (w3d1) | d29 (w5d1) | d43 (w7d1) | d64 (w10d1) | w17–21 | w23–27 | w37–41 | w63–67 | ||
Procedures | Visit No | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
Informed Consent | X | Radical Cystectomy week 11–15 | ||||||||||
Inclusion/Exclusion Criteria | X | |||||||||||
Medical History | X | |||||||||||
Prior cancer therapy | X | |||||||||||
ECOG/Performance Status | X | X | X | X | X | X | X | X | X | X | ||
Physical Examination | X | X | X | X | X | X | X | X | X | X | ||
Vital Signs | X | X | X | X | X | X | X | X | ||||
Height/Weight | X | X | X | X | X | X | X | X | ||||
Symptom/Adverse Event Assessment | X | X | X | X | X | X | X | X | X | X | ||
Bladder/surgery specific AEs | X | X | X | X | X | X | X | X | X | X | ||
Concomitant Medication | X | X | X | X | X | X | X | X | ||||
Laboratory tests | X | X | X | X | X | X | X | X | X | X | ||
HIV/Hepatitis test | X | X | ||||||||||
Pregnancy test (Serum) | X | X | ||||||||||
Urine analysis | X | X | X | X | X | X | ||||||
Kidney Ultrasound | X | X | X | X | X | |||||||
Imaging (CT/MRT) | X | X | X | X | ||||||||
Histology assessment | X | X | ||||||||||
QoL-Questionnaires | X | X | X | X | X | |||||||
Exploratory biomarker blood draw | X | X | X | |||||||||
Survival status | X | X | X | X | ||||||||
Review of subsequent therapy | X | X | X | X |